Benchmark starts Abbott with a Buy, sees ‘resilient foundation’ for growth

As previously reported, Benchmark analyst Bruce Jackson initiated coverage of Abbott (ABT) with a Buy rating and $145 price target Abbott’s diversified business model, which does not rely on a single therapy, technology, or geography, gives it “a resilient foundation” for sustainable mid-single digit sales growth and double-digit adjusted EPS growth, the analyst tells investors. Exposure to multiple high-demand healthcare sectors and an expanding international business can help the company “mitigate an uncertain macro climate,” the analyst added.